{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T04:50:08Z","timestamp":1791348608187,"version":"4.3.1"},"reference-count":67,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.xphs.2026.104490","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T15:13:06Z","timestamp":1788016386000},"page":"104490","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Key strategic considerations for pooling multiple drug substance batches in biopharmaceutical drug product manufacturing"],"prefix":"10.1016","volume":"115","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2280-3803","authenticated-orcid":false,"given":"Kashappa Goud","family":"Desai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4502-3751","authenticated-orcid":false,"given":"James D.","family":"Colandene","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.xphs.2026.104490_bib0001","doi-asserted-by":"crossref","first-page":"3031","DOI":"10.1002\/jps.22545","article-title":"A new roadmap for biopharmaceutical drug product development: integrating development, validation, and quality by design","volume":"100","author":"Martin-Moe","year":"2011","journal-title":"J Pharm Sci"},{"issue":"5s","key":"10.1016\/j.xphs.2026.104490_bib0002","first-page":"36","article-title":"Critical factors for fill\u2013finish manufacturing of biologics","volume":"14","author":"Kovarcik","year":"2016","journal-title":"BioProcess Int"},{"key":"10.1016\/j.xphs.2026.104490_bib0003","series-title":"Development of Biopharmaceutical Drug-Device Products","first-page":"405","article-title":"Chapter 17: scale-down models for robust biologics drug product process development","author":"Deshmukh","year":"2020"},{"key":"10.1016\/j.xphs.2026.104490_bib0004","series-title":"Adv Chem Eng","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/bs.ache.2022.03.005","article-title":"Fill-finish: large-scale manufacturing considerations","volume":"59","author":"Cieri","year":"2022"},{"issue":"3","key":"10.1016\/j.xphs.2026.104490_bib0005","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1021\/bp070462h","article-title":"Current perspectives on stability of protein drug products during formulation, fill and finish operations","volume":"24","author":"Rathore","year":"2008","journal-title":"Biotechnol Prog"},{"key":"10.1016\/j.xphs.2026.104490_bib0006","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S1387-2656(02)08004-3","article-title":"Protein formulation and fill-finish operations","volume":"8","author":"Patro","year":"2002","journal-title":"Biotechnol Annu Rev"},{"key":"10.1016\/j.xphs.2026.104490_bib0007","series-title":"Quality by Design for Biopharmaceutical Drug Product Development","first-page":"159","article-title":"Drug substance frozen storage and thawing","author":"Lam","year":"2015"},{"key":"10.1016\/j.xphs.2026.104490_bib0008","series-title":"Therapeutic Protein Drug Products","first-page":"83","article-title":"5 - Compounding and filling: drug substance to drug product","author":"Meyer","year":"2012"},{"issue":"10","key":"10.1016\/j.xphs.2026.104490_bib0009","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1016\/j.xphs.2022.05.004","article-title":"Mixing of monoclonal antibody formulated drug substance solutions in square disposable vessels","volume":"111","author":"Nakach","year":"2022","journal-title":"J Pharm Sci"},{"issue":"12","key":"10.1016\/j.xphs.2026.104490_bib0010","doi-asserted-by":"crossref","first-page":"3932","DOI":"10.1016\/j.xphs.2019.09.001","article-title":"Mixing of a mAb formulation in a new magnetically coupled single-use mixing system: key learnings of preliminary experimental and computational evaluation","volume":"108","author":"Desai","year":"2019","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2026.104490_bib0011","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3390\/membranes12050524","article-title":"Comparative evaluation of the performance of sterile filters for bioburden protection and final fill in biopharmaceutical processes","volume":"12","author":"Na","year":"2022","journal-title":"Membranes"},{"issue":"3","key":"10.1016\/j.xphs.2026.104490_bib0012","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.xphs.2021.09.016","article-title":"Syringe filling of high-concentration mAb products using peristaltic pump-based mechanism: challenges and mitigation strategies","volume":"111","author":"Desai","year":"2022","journal-title":"J Pharm Sci"},{"issue":"12","key":"10.1016\/j.xphs.2026.104490_bib0013","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1016\/j.xphs.2017.08.005","article-title":"Syringe filling of high-concentration mAb formulation: slow suck-back pump speed prevented filling needle clogging","volume":"106","author":"Hanslip","year":"2017","journal-title":"J Pharm Sci"},{"issue":"3","key":"10.1016\/j.xphs.2026.104490_bib0014","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.xphs.2018.10.031","article-title":"Syringe filling of a high-concentration mAb formulation: experimental, theoretical, and computational evaluation of filling process parameters that influence the propensity for filling needle clogging","volume":"108","author":"Hanslip","year":"2019","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104490_bib0015","series-title":"Lyophilized Biologics and Vaccines: Modality-Based Approaches","first-page":"361","article-title":"Recent trends in lyophilized delivery devices and packaging","author":"Janssen","year":"2015"},{"key":"10.1016\/j.xphs.2026.104490_bib0016","series-title":"Lyophilized Biologics and Vaccines: Modality-Based Approaches","first-page":"121","article-title":"Lyophilization of therapeutic proteins in vials: process scale-up and advances in quality by design","author":"Wang","year":"2015"},{"key":"10.1016\/j.xphs.2026.104490_bib0017","unstructured":"21 CFR Part 210. Current good manufacturing practice in manufacturing, processing, packing, or holding of drugs; general. https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-C\/part-210."},{"key":"10.1016\/j.xphs.2026.104490_bib0018","unstructured":"21 CFR Part 211, Subpart E - control of components and drug product containers and closures. https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-C\/part-211\/subpart-E."},{"key":"10.1016\/j.xphs.2026.104490_bib0019","unstructured":"21 CFR Part 211, Subpart F - production and process controls. https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-C\/part-211\/subpart-F."},{"key":"10.1016\/j.xphs.2026.104490_bib0020","unstructured":"European Commission. Brussels, 16.2.2022, C(2022) 843 Final. guidelines. The rules governing medicinal products in the European Union. Volume 4. EU guidelines for good manufacturing practice for medicinal products for human and veterinary use.https:\/\/health.ec.europa.eu\/latest-updates\/eudralex-volume-4-eu-guidelines-good-manufacturing-practice-medicinal-products-human-and-veterinary-2022-02-21_en."},{"key":"10.1016\/j.xphs.2026.104490_bib0021","unstructured":"European Commission. Brussels, 30 March 2015. EudraLex volume 4. EU guidelines for good manufacturing practice for medicinal products for human and veterinary use. annex 15: qualification and validation. https:\/\/www.gmp-compliance.org\/files\/guidemgr\/2015-10_annex15.pdf."},{"key":"10.1016\/j.xphs.2026.104490_bib0025","unstructured":"Health Canada. Minister of Health. Information and submission requirements for biosimilar biologic drugs. Adopted on 2010-03-05.https:\/\/www.canada.ca\/content\/dam\/hc-sc\/documents\/services\/drugs-health-products\/biologics-radiopharmaceuticals-genetic-therapies\/applications-submissions\/guidance-documents\/information-submission-requirements-biosimilar-biologic-drugs\/information-submission-requirements-biosimilar-biologic-drugs.pdf."},{"key":"10.1016\/j.xphs.2026.104490_bib0026","year":"2004"},{"key":"10.1016\/j.xphs.2026.104490_bib0027","year":"2012"},{"key":"10.1016\/j.xphs.2026.104490_bib0028","series-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Evaluation for Stability Data Q1E","year":"2003"},{"key":"10.1016\/j.xphs.2026.104490_bib0029","series-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Pharmaceutical Development Q8(R2)","year":"2009"},{"key":"10.1016\/j.xphs.2026.104490_bib0030","series-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Pharmaceutical Quality System Q10","year":"2008"},{"key":"10.1016\/j.xphs.2026.104490_bib0031","series-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Quality of Biotechnological Products: Stability Testing of Biotechnological\/Biological Products Q5C","year":"1995"},{"key":"10.1016\/j.xphs.2026.104490_bib0032","series-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Quality Risk Management Q9","year":"2005"},{"key":"10.1016\/j.xphs.2026.104490_bib0033","series-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Technical and Regulatory Considerations for Pharmaceutical Product Lifecycle Management Q12","year":"2019"},{"key":"10.1016\/j.xphs.2026.104490_bib0036","unstructured":"World Health Organization. Guidelines on the quality, safety and efficacy of biotherapeutic protein products prepared by recombinant DNA technology, replacement of Annex 3 of WHO Technical Report Series, No. 814.https:\/\/cdn.who.int\/media\/docs\/default-source\/biologicals\/biotherapeutics\/trs_987_annex4.pdf?sfvrsn=d4ba378a_5&download=true."},{"key":"10.1016\/j.xphs.2026.104490_bib0037","series-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. Q7","year":"2000"},{"issue":"1","key":"10.1016\/j.xphs.2026.104490_bib0038","first-page":"163","article-title":"Impact of process validation and equipment qualification in production of bio-therapeutics","volume":"5","author":"Ghosh","year":"2022","journal-title":"JABET"},{"key":"10.1016\/j.xphs.2026.104490_bib0039","unstructured":"World Health Organization (WHO) Good manufacturing practices for biological products. Replacement of Annex 1 of WHO Technical Report Series, No. 822.https:\/\/www.who.int\/docs\/default-source\/biologicals\/gmp\/annex-2-who-good-manufacturing-practices-for-biological-products.pdf."},{"issue":"8","key":"10.1016\/j.xphs.2026.104490_bib0041","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1016\/j.xphs.2020.03.024","article-title":"A review on mixing-induced protein particle formation: the puzzle of bottom-mounted mixers","volume":"109","author":"Gikanga","year":"2020","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104490_bib0045","unstructured":"National Medical Products Administration. https:\/\/english.nmpa.gov.cn\/."},{"key":"10.1016\/j.xphs.2026.104490_bib0046","unstructured":"Pharmaceuticals and Medical Devices Agency. https:\/\/www.pmda.go.jp\/english\/review-services\/gmp-qms-gctp\/0003.html."},{"key":"10.1016\/j.xphs.2026.104490_bib0047","unstructured":"Pharmaceuticals and Medical Devices Agency. Revision of Japanese Medical Device QMS requirements. https:\/\/www.pmda.go.jp\/english\/review-services\/regulatory-info\/0004.html."},{"key":"10.1016\/j.xphs.2026.104490_bib0048","unstructured":"The Ministry of Health, Labour and Welfare. https:\/\/www.mhlw.go.jp\/english\/policy\/health-medical\/pharmaceuticals\/index.html."},{"issue":"7","key":"10.1016\/j.xphs.2026.104490_bib0049","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1016\/j.xphs.2018.03.017","article-title":"Japan-specific key regulatory aspects for development of new biopharmaceutical drug products","volume":"107","author":"Desai","year":"2018","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.xphs.2026.104490_bib0050","unstructured":"Pharmaceuticals and Medical Devices Agency. https:\/\/www.pmda.go.jp\/files\/000156658.pdf."},{"key":"10.1016\/j.xphs.2026.104490_bib0051","unstructured":"Association of South East Asian Nations (ASEAN). Annex VIII - ASEAN guidelines on good manufacturing practice for traditional medicines. https:\/\/asean.org\/wp-content\/uploads\/2017\/09\/ASEAN-Guideline-on-GMP-for-TM-Appendices-2-june-2015-with-disclaimer....pdf."},{"key":"10.1016\/j.xphs.2026.104490_bib0052","unstructured":"Association of South East Asian Nations (ASEAN). ASEAN Common Technical Requirements (ACTR). https:\/\/asean.org\/wp-content\/uploads\/2021\/08\/ASEAN-Common-Technical-Requirements-ACTR.pdf."},{"key":"10.1016\/j.xphs.2026.104490_bib0054","unstructured":"Central Drugs Standard Control Organization, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India. https:\/\/cdsco.gov.in\/opencms\/opencms\/en\/Home\/."},{"issue":"1","key":"10.1016\/j.xphs.2026.104490_bib0055","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/nbt0109-26","article-title":"Quality by design for biopharmaceuticals","volume":"27","author":"Rathore","year":"2009","journal-title":"Nat Biotechnol"},{"key":"10.1016\/j.xphs.2026.104490_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.bdr.2020.100172","article-title":"Smart pharmaceutical manufacturing: Ensuring end-to-end traceability and data integrity in medicine production","volume":"24","author":"Leal","year":"2021","journal-title":"Big Data Res"},{"key":"10.1016\/j.xphs.2026.104490_bib0057","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Center for Veterinary Medicine (CVM). Data integrity and compliance with drug CGMP, questions and answers, guidance for industry. Pharmaceutical quality\/manufacturing standards (CGMP). December 2018. https:\/\/www.fda.gov\/media\/119267\/download."},{"key":"10.1016\/j.xphs.2026.104490_bib0058","series-title":"International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. ICH Harmonised Tripartite Guideline. Stability Testing of New Drug Substances and Products, Q1A(R2)","year":"2003"},{"issue":"(3)i","key":"10.1016\/j.xphs.2026.104490_bib0060","first-page":"16","article-title":"Stability testing: Monitoring biological product quality over time","volume":"19","author":"Scott","year":"2021","journal-title":"BioProcess Int"},{"key":"10.1016\/j.xphs.2026.104490_bib0061","unstructured":"World Health Organization (WHO). 50th Report of the WHO expert Committee on Specifications for Pharmaceutical preparations - TRS, No. 996. Annex 2. https:\/\/iris.who.int\/bitstream\/handle\/10665\/255338\/9789241209960-eng.pdf?sequence=1."},{"key":"10.1016\/j.xphs.2026.104490_bib0062","series-title":"Pharmaceutical Manufacturing Deviation and Failure Investigations: Principles, Practices, and Case Studies","first-page":"53","article-title":"Management of deviation and failure investigation","author":"Pazhayattil","year":"2025"},{"key":"10.1016\/j.xphs.2026.104490_bib0063","unstructured":"Center for Drug Evaluation and Research. Application number: 761091Orig1s000. Product quality review(s). Complete response BLA 761091. Trastuzumab-pkrb. Celltrion, Inc. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/761091Orig1s000ChemR.pdf?"},{"key":"10.1016\/j.xphs.2026.104490_bib0064","unstructured":"Center for Drug Evaluation and Research. Application Number: 125521Orig1s000. Administrative and correspondence documents. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2016\/125521Orig1s000Admincorres.pdf?"},{"key":"10.1016\/j.xphs.2026.104490_bib0065","unstructured":"Center for Drug Evaluation and Research. Application Number: 761072Orig1s000. Administrative and correspondence documents.https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2017\/761072Orig1s000Admincorres.pdf?"},{"key":"10.1016\/j.xphs.2026.104490_bib0066","unstructured":"Health Canada. Notice of Compliance to Janssen Inc. for the drug product Talvey. Quality basis for decision. https:\/\/dhpp.hpfb-dgpsa.ca\/review-documents\/resource\/SBD1732553847408."},{"key":"10.1016\/j.xphs.2026.104490_bib0067","unstructured":"Health Canada. Summary basis of decision for anthim. https:\/\/dhpp.hpfb-dgpsa.ca\/review-documents\/resource\/SBD00516."},{"key":"10.1016\/j.xphs.2026.104490_bib0068","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use. EMA\/CHMP\/220699\/2019. Assessment report. Ultomiris. Procedure no. EMEA\/H\/C\/004954\/0000. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/ultomiris-epar-public-assessment-report_en.pdf."},{"key":"10.1016\/j.xphs.2026.104490_bib0069","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use. EMA\/CHMP\/476618\/2011. Assessment report. Kalbitor. Ecallantide. Procedure no.: EMEA\/H\/C\/002200. https:\/\/www.ema.europa.eu\/en\/documents\/withdrawal-report\/withdrawal-assessment-report-kalbitor_en.pdf."},{"key":"10.1016\/j.xphs.2026.104490_bib0070","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). EMA\/596513\/2015. Assessment report. Solumarv. Procedure No. EMEA\/H\/C\/003858\/0000. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/solumarv-epar-public-assessment-report_en.pdf."},{"key":"10.1016\/j.xphs.2026.104490_bib0071","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). EMA\/198412\/2025. Assessment report. Rolcya. Denosumab. Procedure No. EMEA\/H\/C\/006507\/0000. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/rolcya-epar-public-assessment-report_en.pdf?"},{"key":"10.1016\/j.xphs.2026.104490_bib0072","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). EMA\/77774\/2026. Assessment report. Zandoriah (teriparatide). Procedure no. EMEA\/H\/C\/006688\/0000. https:\/\/www.ema.europa.eu\/en\/documents\/assessment-report\/zandoriah-epar-public-assessment-report_en.pdf."},{"key":"10.1016\/j.xphs.2026.104490_bib0074","unstructured":"European Medicines Agency. Committee for Medicinal Products for Human Use (CHMP). Questions and answers on post approval change management protocols (PACMP). EMA\/CHMP\/QWP\/586330\/2010 Rev 1. 1 December 2025.https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/questions-answers-post-approval-change-management-protocols-pacmp-revision-1_en.pdf."},{"issue":"2","key":"10.1016\/j.xphs.2026.104490_bib0075","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/j.xphs.2023.11.004","article-title":"Roadmap for drug product development and manufacturing of biologics","volume":"113","author":"Sampathkumar","year":"2024","journal-title":"J Pharm Sci"},{"issue":"4","key":"10.1016\/j.xphs.2026.104490_bib0076","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.xphs.2021.09.030","article-title":"Stress factors in protein drug product manufacturing and their impact on product quality","volume":"111","author":"Das","year":"2022","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2026.104490_bib0077","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.biologicals.2016.06.004","article-title":"Process characterization and design space definition","volume":"44","author":"Hakemeyer","year":"2016","journal-title":"Biologicals"},{"key":"10.1016\/j.xphs.2026.104490_bib0078","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.biologicals.2020.06.008","article-title":"A cross-industry forum on benchmarking critical quality attribute identification and linkage to process characterization studies","volume":"67","author":"Demmon","year":"2020","journal-title":"Biologicals"},{"issue":"3","key":"10.1016\/j.xphs.2026.104490_bib0079","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.xphs.2021.09.015","article-title":"A road map to GMP readiness for protein therapeutics \u2013 drug product process development for clinical supply","volume":"111","author":"Liebner","year":"2022","journal-title":"J Pharm Sci"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926003400?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354926003400?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:55:58Z","timestamp":1791345358000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354926003400"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":67,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["S0022354926003400"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104490","relation":{},"ISSN":["0022-3549"],"issn-type":[{"value":"0022-3549","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Key strategic considerations for pooling multiple drug substance batches in biopharmaceutical drug product manufacturing","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2026.104490","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104490"}}